Close Menu

antisense

The company said it intends to use the technology to develop infectious disease diagnostics, with an initial focus on SARS-CoV-2.

Genuity Science, formerly known as WuXi NextCode, will receive a combination of upfront, development milestone, and product royalty payments under the deal.

In Science this week: crystal structures of single-stranded RNA bacteriophages found through metagenomic studies, more.

In PNAS this week: effect of premature termination codons in the DMD gene, knock-down of DUX4 in facioscapulohumeral muscular dystrophy, and more.

As part of the deal, Ionis also took a $10 million equity stake in Empirico and was the lead investor in the company's Series A-2 financing round.

UMich's Arul Chinnaiyan plans to use the funding to develop new tools and technologies to identify biomarkers for cancer diagnosis and treatment.

The arrangement includes exclusive rights to certain disease targets and non-exclusive rights to platform technologies.

NEW YORK (GenomeWeb) — Isis Pharmaceuticals and Santaris Pharma are currently negotiating a settlement to their roughly three-year-old patent-infringement lawsuit and believe there is "strong potential to settle" the litigation instead of going to trial, according to court documents filed this mo

NEW YORK (GenomeWeb) – While its primary focus remains on a class of novel cell membrane-disrupting antimicrobials, privately held Lakewood-Amedex is ramping up work on proprietary, orally delivered antisense molecules, with an eye to tackling influenza and, eventually, other viral diseases.

NEW YORK (GenomeWeb) – Marina Biotech this week took another step toward reestablishing itself as a player in the nucleic acids drug sector, regaining compliance with US Securities and Exchange Commission financial reporting requirements with the submission of the requisite information for 2012,

Pages

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.

CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.

Researchers in France are developing a new, fast test for SARS-CoV-2 that initial testing indicates may be highly accurate, the Guardian says.

In Cell this week: analysis of fitness patterns among SARS-CoV-2 isolates, single-cell transcriptome analysis of immune features in COVID-19, and more.